| 3/15/2016 | PP | Market Commentary: Valeant woes cast a pall over convertible biotech/health care; energy shows resilience
|
| 3/15/2016 | CV | Market Commentary: Valeant woes cast a pall over convertible biotech/health care; energy shows resilience
|
| 2/29/2016 | PP | Market Commentary: Horizon Pharma contracts as shares drop; Priceline adds in line; Newmont expands slightly
|
| 2/29/2016 | CV | Market Commentary: Horizon Pharma contracts as shares drop; Priceline adds in line; Newmont expands slightly
|
| 6/11/2012 | CV | Market Commentary: Alpha Natural gains on hedge despite coal share slump; Navistar up on hedge; Omnicare in line
|
| 2/24/2012 | BK | Endo repaid $140 million of term loan in fourth quarter of 2011
|
| 2/24/2012 | CV | Market Commentary: Interpublic slips in active trade on call; Salesforce.com active, lower; Savient weakens
|
| 8/9/2011 | CV | Endo Pharmaceuticals' 1.75% notes due 2015 become convertible
|
| 6/20/2011 | BKCVHY | S&P assigns Endo loan BBB-, notes BB-
|
| 6/20/2011 | BK | Market Commentary: Las Vegas Sands softens as Venetian Macau pulls B loan; Husky International tweaks deal
|
| 6/7/2011 | BK | Endo trims term B to $700 million, cuts spread to Libor plus 300 bps
|
| 6/7/2011 | BK | Market Commentary: AutoTrader, Endo, U.S. Renal Care, Legendary Pictures break; Avaya rises on IPO chatter
|
| 6/7/2011 | HY | Market Commentary: Freescale drive-by, Symbion, Norske Skog price; Arch, Teleflex ahead; Sino-Forest sours again
|
| 6/6/2011 | HY | Market Commentary: Primary slacks off with no new pricings; market awaits Symbion; Sino-Forest gyrates; Compton up
|
| 6/3/2011 | BK | Market Commentary: SRAM breaks; Gibson Energy, Il Fornaio revise deals; AWAS Aviation finalizes spread
|
| 6/3/2011 | HY | New Issue: Endo Pharmaceuticals prices upsized $900 million two-part senior notes
|
| 6/3/2011 | HY | Market Commentary: Vulcan mega-deal, Endo, W&T price to end short week; Sino-Forest chopped down after report
|
| 5/31/2011 | HY | Endo Pharmaceuticals sets structure for $700 million senior notes
|
| 5/31/2011 | HY | Market Commentary: Cinemark, Puget drive-bys price in quiet post-holiday market; Arch, Vulcan slate mega-deals
|
| 5/31/2011 | CVLM | American Medical Systems' 3.25%, 4% convertibles will likely be putable after Endo merger
|
| 5/27/2011 | HY | Market Commentary: Market winds down before holiday; recent deals see demand; McClatchy firms on asset sale
|
| 5/26/2011 | BKCVHY | Moody's rates Endo loan Ba1, notes Ba3
|
| 5/26/2011 | BKCVHYIG | S&P cuts Endo, rates loan BBB- and notes BB-
|
| 5/26/2011 | HY | Endo Pharmaceuticals to start roadshow Tuesday for $700 million notes
|
| 5/26/2011 | HY | Market Commentary: GM, WCA, Oil States, International Auto price, move up; Endo, W&T slate; funds up $94 million
|
| 5/23/2011 | BK | Endo Pharmaceuticals talks $900 million term B at Libor plus 325 bps
|
| 5/23/2011 | BK | Market Commentary: SymphonyIRI breaks; JBS, Securus, Exopack revise deals; Endo, FMG price talk surfaces
|
| 5/18/2011 | BK | Endo Pharmaceuticals sets Monday launch for $900 million term loan B
|
| 5/18/2011 | BK | Market Commentary: Select Medical, Dunkin' break; FairPoint still under pressure; Xerium revises deal
|
| 5/5/2011 | BK | Market Commentary: Sensus, Town Sports break; Harland Clarke down on numbers; primary sees wave of deal changes
|
| 5/5/2011 | BK | Endo launches $2 billion pro rata; $900 million B expected May 16 week
|
| 4/18/2011 | BK | American Medical Systems gets $250 million five-year revolver
|
| 4/14/2011 | BKHY | Endo plans $2.9 billion facility, $700 million bonds for AMS purchase
|
| 4/11/2011 | CV | Market Commentary: American Medical mixed on hedge on takeout news; Endo lower; AMR off; PPL, Hercules on tap
|
| 4/11/2011 | BKCVHY | Endo looking to deleverage after American Medical Systems acquisition
|
| 4/11/2011 | HY | Market Commentary: Vail, Spencer price; hospital bonds hit on Tenet suit; Level 3, Global Crossing up on deal
|
| 4/11/2011 | BKCVHY | Moody's may cut Endo notes
|
| 4/11/2011 | BKCVHY | S&P: American Medical Systems unchanged
|
| 4/11/2011 | BKHY | Endo plans term loans and bonds for purchase of American Medical
|
| 4/11/2011 | BKHY | S&P puts Endo on watch
|
| 12/1/2010 | BK | Market Commentary: Ford rises; TransDigm, Harbourvest, Education tweak deals; Applied Systems ups deadline
|
| 11/19/2010 | HY | Market Commentary: Petco, upsized Paetec price, both rise to close out $10 billion week; secondary slide resumes
|
| 11/18/2010 | HY | New Issue: Endo Pharmaceuticals prices $400 million 7% 10-year notes at 99.105 to yield 7 1/8%
|
| 11/15/2010 | HY | Moody's rates Endo notes Ba2
|
| 11/15/2010 | HY | Market Commentary: Ally $1 billion drive-by leads $2.4 billion session, falls in trading; GM gains as IPO looms
|
| 11/15/2010 | BK | Endo Pharmaceuticals Holdings upsizes term loan to $400 million
|
| 11/15/2010 | BK | Market Commentary: MedAssets breaks; Bucyrus dips on acquisition; Sabre rises; Petco, Endo, Royall tweak deals
|
| 11/15/2010 | HY | Endo Pharmaceuticals to price $400 million 10-year notes Thursday
|
| 11/1/2010 | BK | Endo Pharmaceuticals amends revolver, permitting incremental loans
|
| 11/1/2010 | BK | Market Commentary: Univison up with ratings change; Getty, Focus Brands, Gateway, Global Tel*Link revise deals
|
| 10/13/2010 | BK | Endo launches $700 million credit facility at Libor plus 250 bps
|
| 10/13/2010 | BK | Market Commentary: MGM Resorts rises; CCGI, DaVita tweak deals; Ascend pulls loan; Global Tel sets launch, talk
|
| 10/12/2010 | BK | Endo Pharmaceuticals to launch new credit facility on Wednesday
|
| 10/12/2010 | BK | Market Commentary: AutoTrader.com breaks; Sun tweaks loan; Deltek, Endo, Omnova, Fibertech, Viking ready deals
|
| 10/4/2010 | CV | Market Commentary: Microsoft flat to lower after stock downgrade; Endo Pharmaceuticals edges up; TRW slips
|
| 9/28/2010 | BK | Endo Pharmaceuticals plans $400 million term for Qualitest purchase
|
| 10/22/2009 | BK | Endo Pharmaceuticals gets $300 million revolving credit facility
|
| 10/15/2009 | SS | D.E. Shaw reports sale of 1.3 million shares of Endo Pharmaceuticals
|
| 10/5/2009 | HYPV | Endo buys $48 million of Ledgemont's 16% notes in tender offer
|
| 8/28/2009 | SS | D.E. Shaw reports sale of 1.9 million shares of Endo Pharmaceuticals
|
| 3/23/2009 | SS | Endo Pharmaceuticals buys Indevus for $370 million
|
| 3/19/2009 | SS | Endo Pharmaceuticals accepts 89% of Indevus shares in completed tender offer
|
| 3/11/2009 | SS | D.E. Shaw sells 1.5 million shares of Endo Pharmaceuticals
|
| 3/2/2009 | SS | Endo Pharmaceuticals extends subsequent offering period for remaining Indevus shares
|
| 2/23/2009 | SS | Endo Pharmaceuticals begins subsequent offer for remaining Indevus shares
|
| 2/5/2009 | SS | Indevus settles lawsuits, agrees to lower termination fee in proposed merger with Endo
|
| 1/6/2009 | SS | Market Commentary: Endo buyout likely to close; Rohm & Haas stock falls below Dow bid; Johnson & Johnson extends offer
|
| 1/5/2009 | SS | Endo Pharmaceuticals to buy Indevus for $370 million
|
| 8/7/2008 | SP | New Issue: JPMorgan prices $2.07 million 14% reverse exchangeables linked to Endo Pharmaceuticals
|
| 4/30/2008 | SS | Endo to add William Spengler to expanded board as part of settlement with D.E. Shaw
|
| 4/14/2008 | CV | Market Commentary: Wachovia adds on debut; CapitalSource gets another look after deal with California bank; Endo trades well
|
| 4/10/2008 | CV | New Issue: Endo Pharmaceuticals prices $379.5 million seven-year convertibles to yield 1.75%, up 17.5%
|
| 4/10/2008 | CV | Market Commentary: Endo jumps on debut; takeout news lifts Millenium, other biotechs gain; NatCity in play
|
| 4/9/2008 | CV | Endo Pharmaceuticals to price $345 million seven-year convertibles to yield 1.625%-2.125%, up 15%-20%
|
| 4/9/2008 | CV | Market Commentary: Convertibles mostly softer; Citigroup, WaMu ease; Exubera news hits Nektar; Virgin, Endo to price
|
| 4/7/2008 | SP | New Issue: JPMorgan prices $3.42 million 15% reverse exchangeables linked to Endo Pharmaceuticals
|
| 3/5/2008 | SS | Endo Pharmaceuticals disagrees with shareholder's claim that it refused to meet
|
| 2/28/2008 | SS | D.E. Shaw weighs in on Endo Pharmaceutical's CEO search, investor could seek board representation
|
| 12/21/2007 | SS | D.E. Shaw increases ownership of Endo to 9.6%
|
| 11/21/2007 | SS | D.E. Shaw buys more shares of Endo Pharmaceuticals
|
| 10/12/2007 | SS | D.E. Shaw ups Endo Pharmaceuticals stake to 7.3%
|
| 7/30/2007 | SS | D.E. Shaw recommends Endo Pharmaceuticals buy back shares, seek alternatives
|
| 6/20/2007 | SP | New Issue: Eksportfinans prices $1.2 million 12.05% reverse convertibles linked to Endo via Natixis
|
| 10/20/2006 | BT | Jefferies puts Endo on hold
|
| 10/20/2006 | BT | Endo outperform by RBC
|
| 10/19/2006 | BT | Endo rated outperform by RBC
|
| 10/19/2006 | BT | Endo Pharmaceuticals' cash up at $647.7 million, Q3 sales fall
|
| 10/18/2006 | BT | Bear puts Endo at peer perform
|
| 10/18/2006 | BT | Endo on hold by Jefferies
|
| 10/18/2006 | BT | RBC rates Endo at outperform
|
| 10/13/2006 | BT | RBC rates Endo at outperform
|
| 10/13/2006 | BT | Jefferies puts Endo on hold
|
| 10/9/2006 | BT | Jefferies: CollaGenex, Forest Labs beat Q3 estimates; Connetics lags behind
|
| 10/3/2006 | BT | Jefferies puts Endo on hold
|
| 10/3/2006 | BT | Endo at outperform by RBC
|
| 10/3/2006 | BT | Market Commentary: Acorda shoots up 32%; Isis lower after analyst day; Gilead off 3.5%, Myogen eases; Amgen better
|
| 9/12/2006 | BT | Endo at outperform by RBC
|
| 8/29/2006 | BT | Jefferies updates specialty pharmaceutical market
|
| 8/29/2006 | BT | Jefferies downgrades Endo to hold
|
| 8/29/2006 | BT | Endo kept at outperform by RBC
|
| 8/29/2006 | BT | Market Commentary: Teva lower; Endo, Penwest up; StemCells gains 7%; Nastech higher; Hemispherx rises 11%
|
| 8/28/2006 | BT | Endo settles oxycodone patent infringement litigation with Purdue, will sell products until end of year
|
| 8/17/2006 | BT | RBC keeps Endo at outperform
|
| 8/17/2006 | BT | Endo at buy by Jefferies
|
| 8/16/2006 | BT | Penwest sues Endo for Opana ER
|
| 7/24/2006 | BT | Endo says Opana now commercially available to treat pain
|
| 7/21/2006 | BT | Jefferies maintains Endo at buy
|
| 7/21/2006 | BT | Endo kept at outperform by RBC
|
| 7/20/2006 | BT | Endo Pharmaceuticals reports $57.6 million second quarter net income
|
| 7/19/2006 | BT | Endo Pharmaceuticals, Vernalis file supplemental NDA for Frova
|
| 6/26/2006 | BT | Jefferies reiterates Endo at buy
|
| 6/26/2006 | BT | Endo upgraded to outperform by RBC
|
| 6/23/2006 | BT | Endo receives FDA approval for pain drug Opana; revises 2006 estimates
|
| 6/23/2006 | BT | Jefferies reiterates Endo Pharma at buy
|
| 6/23/2006 | BT | Market Commentary: Neurocrine, DOV fall on Pfizer nixing indiplon funding; Endo rises 10%, Penwest gains 37%
|
| 5/8/2006 | BT | Jefferies gives Endo a buy rating
|
| 5/8/2006 | BT | Jefferies specialty pharmaceuticals report
|
| 5/8/2006 | BT | Vernalis, Endo: Frova meets primary endpoint in second phase 3 study to prevent menstrual migraine
|
| 4/28/2006 | BT | SkyePharma's DepoDur for pain approved by U.K. agency
|
| 4/21/2006 | BT | Jefferies keeps Endo at buy
|
| 4/21/2006 | BT | SkyePharma, Endo to stop development of Propofol anesthetic
|
| 4/20/2006 | BT | Endo Pharmaceuticals first-quarter 2006 net sales rise 48.8% to $205 million
|
| 4/20/2006 | BT | Endo at buy by Jefferies
|
| 4/18/2006 | BT | Endo reiterated at buy by Jefferies
|
| 3/22/2006 | BT | New Issue: Endo secondary sale of 10.5 million shares sold at $32.20 each versus $33.28 close
|
| 3/22/2006 | BT | Market Commentary: Cephalon seesaws; Nabi zooms; Endo drops; Insmed off; Elan, Biogen drop; King launches deal
|
| 2/16/2006 | BT | Jefferies puts Endo at buy
|
| 2/15/2006 | BT | Endo at buy by Jefferies
|
| 2/15/2006 | BT | Endo Pharmaceuticals sees sales jump 33% year over year
|
| 2/6/2006 | BT | Endo to continue to market its bioequivalent version of OxyContin
|
| 2/2/2006 | BT | Endo rating altered to buy/high risk by Citigroup
|
| 2/2/2006 | BT | Jefferies keeps Endo at buy
|
| 2/2/2006 | BT | Market Commentary: Valera debut shares gain 10%; Theravance up; ImClone sinks; Nabi rockets; Teva pressured
|
| 2/1/2006 | BT | Market Commentary: Vertex gains; SGX debuts higher; Angiotech up; Alnylam off; DUSA dives; Endo slides; Isis bounces
|
| 2/1/2006 | BT | Endo's OxyContin patent case with Purdue goes back to court
|
| 2/1/2006 | BT | Jefferies rates Endo at buy
|
| 1/25/2006 | BT | Durect, Endo extend Chronogesic pact
|
| 1/20/2006 | BT | Market Commentary: DOR BioPharma stock jumps 15.6% on orBec news, equity line; Shire, Impax settle patent suit
|
| 1/19/2006 | BT | New Issue: Endo Pharma $417.75 million secondary sale priced at $27.85
|
| 1/19/2006 | BT | Jefferies gives Endo Pharma buy rating
|
| 1/19/2006 | BT | Market Commentary: Endo Pharmaceuticals prices $417.75 million secondary stock sale; Procyon to merge with Cellpep
|
| 1/10/2006 | BT | Jefferies lowers Endo price target to $33.50
|
| 1/3/2006 | BT | Merrill raises Endo price target to $35
|
| 12/22/2005 | BT | Endo provides additional safety, efficacy information to FDA for oxymorphone tablets
|
| 11/16/2005 | BT | Endo says Celebrex, Lidoderm research shows both drugs significantly improve chronic low back pain
|
| 10/21/2005 | BT | Citigroup says Endo still a buy
|
| 10/21/2005 | BT | Jefferies lowers Endo price target to $31
|
| 10/20/2005 | BT | Jefferies maintains Endo buy rating
|
| 10/13/2005 | BT | Market Commentary: Human Genome finds volatility players get it; Access Pharma off, then steadies; Endo, Noven firm
|
| 10/12/2005 | BT | Endo Pharmaceuticals greenshoe exercised in full, upping stock offer to 33.35 million shares
|
| 10/12/2005 | BT | Endo receives outperform rating from Leerink Swann
|
| 10/6/2005 | BT | New Issue: Endo secondary of upsized 29 million shares priced at $26.04, pat with close
|
| 10/6/2005 | BT | Market Commentary: Endo, Panacos mixed after deals; Invitrogen off; Oscient plunges; Human Genome continues spiral
|
| 10/3/2005 | BT | Market Commentary: Dynavax on for next week's slate; Celgene buying on weakness aids a positive close; Endo lower again
|
| 9/30/2005 | BT | Market Commentary: Predix IPO price range emerges; Genomic, Avalon, Sunesis a mix; Progenics up; BioDelivery slides
|
| 9/28/2005 | BT | Market Commentary: Panacos, SkyePharma add to deal slate; Incyte, Endo drop on news; Electro-Optic rejigs talk, syndicate
|
| 9/27/2005 | BT | Market Commentary: Sunesis sinks after below-range IPO; Biogen, Elan bounce then retreat; Genentech sharply lower
|
| 9/26/2005 | BT | Endo announces secondary offering of 26 million shares for next week's business
|
| 9/26/2005 | BT | Market Commentary: Eye drug names viewed in mixed fashion; Ligand gains on hopes of sale; Endo plunges on secondary
|
| 8/18/2005 | BT | Endo Pharmaceuticals rated buy by Jefferies
|
| 7/25/2005 | BT | Market Commentary: Teva purchases Ivax, both higher; Endo Pharma climbs on possible sale of Ivax pain drug
|
| 7/22/2005 | BT | Endo Pharma kept by Jefferies at buy
|
